Multicenter Phase II Clinical Trial of Nilotinib for Patients With Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia From the East Japan CML Study Group Evaluation of Molecular Response and the Efficacy and Safety of Nilotinib

Biomarker Research - United Kingdom
doi 10.1186/2050-7771-2-6
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Cost-Effectiveness of Dasatinib and Nilotinib for Imatinib-Resistant or -Intolerant Chronic Phase Chronic Myeloid Leukemia

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2011English

Long-Term Safety and Efficacy of Dasatinib in the Treatment of Chronic-Phase Chronic Myeloid Leukemia Patients Resistant or Intolerant to Imatinib

Blood and Lymphatic Cancer: Targets and Therapy
2014English

Therapeutic Drug Monitoring of Imatinib, Nilotinib, and Dasatinib for Patients With Chronic Myeloid Leukemia

Biological and Pharmaceutical Bulletin
MedicinePharmacologyPharmaceutical Science
2015English

Long-Term Efficacy and Safety of Dasatinib in Patients With Chronic Myeloid Leukemia in Accelerated Phase Who Are Resistant to or Intolerant of Imatinib

Blood Cancer Journal
OncologyHematology
2018English

Pancreatic Enzyme Elevation in Chronic Myeloid Leukemia Patients Treated With Nilotinib After Imatinib Failure

Haematologica
Hematology
2009English

Long-Term Molecular and Cytogenetic Response and Survival Outcomes With Imatinib 400 Mg, Imatinib 800 Mg, Dasatinib, and Nilotinib in Patients With Chronic-Phase Chronic Myeloid Leukaemia: Retrospective Analysis of Patient Data From Five Clinical Trials

The Lancet Haematology
Hematology
2015English

Budget Impact Analysis or Pharmacological Therapy of Chronic Myeloid Leukemia (Cml) With Nilotinib as the Second-Line Treatment in Russian Federation

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2015English

Satisfaction With Information on Nilotinib Treatment in Chronic Myeloid Leukemia Patients

Acta Oncologica
Nuclear MedicineRadiologyHematologyOncologyMedicineImaging
2019English

Complete Molecular Response Induced by Nilotinib in a Patient Previously Treated With Imatinib, Nilotinib and Dasatinib

Clinical Management Issues
MedicineAccountingManagementBusiness
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy